Johnson & Johnson (JNJ), Bayer Receive Favorable FDA Panel Vote for Xarelto
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) and Bayer have gotten a positive vote for its proposed blood thinner.
In a 9-2 vote, a Food and Drug Administration panel voted in favor of recommending Xarelto, a once-a-day anti-clotting pill jointly developed by J&J and Bayer.
Reuters said Xarelto is one of several entrants aimed at replacing risky warfarin for prople with atrial fibrillation, or dangerously irregular heart rhythms. Competitors include Boehringer Ingelheim’s Pradaxa, as well as Pfizer (NYSE: PFE) and Bristol-Myers Squibb's (NYSE: BMY) Eliquis (apixaban). Pradaxa is currently approved for use in heart patients, while Eliquis is currently in clinical trials.
Though the FDA doesn't have to go with the recommendation of a panel, investors are hoping for a positive outcome when the FDA makes its final decision in November.
In a 9-2 vote, a Food and Drug Administration panel voted in favor of recommending Xarelto, a once-a-day anti-clotting pill jointly developed by J&J and Bayer.
Reuters said Xarelto is one of several entrants aimed at replacing risky warfarin for prople with atrial fibrillation, or dangerously irregular heart rhythms. Competitors include Boehringer Ingelheim’s Pradaxa, as well as Pfizer (NYSE: PFE) and Bristol-Myers Squibb's (NYSE: BMY) Eliquis (apixaban). Pradaxa is currently approved for use in heart patients, while Eliquis is currently in clinical trials.
Though the FDA doesn't have to go with the recommendation of a panel, investors are hoping for a positive outcome when the FDA makes its final decision in November.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Provident Financial prices $175M subordinated notes at 6.50%
- GitLab releases version 19.3 with AI gateway and secrets tools
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
